Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease

New England Journal of Medicine

Volumn 357, Issue 19, 2007, Pages 1916-1927

  Fermé, Christophe ^a   Eghbali, Houchingue ^a   Meerwaldt, Jacobus H ^b   Rieux, Chantal ^c   Bosq, Jacques ^a   Berger, Françoise ^d   Girinsky, Théodore ^a   Brice, Pauline ^e   Van'T Veer, Mars B ^f   Walewski, Jan A ^g   Lederlin, Pierre ^h   Tirelli, Umberto ⁱ   Carde, Patrice ^a   Van Den Neste, Eric ⁱ   Gyan, Emmanuel ^j   Monconduit, Mathieu ^k   Diviné, Marine ^l   Raemaekers, John M M ^m   Salles, Gilles ^d   Noordijk, Evert M ⁿ   Creemers, Geert Jan ^o   Gabarre, Jean ^p   Hagenbeek, Anton ^q   Reman, Oumédaly ^r   Blanc, Michel ^s   Thomas, José ^t   Vié, Brigitte ^c   Kluin Nelemans, Johanna C ⁿ   Viseu, Fernando ^u   Baars, Joke W ^v   Poortmans, Philip ^w   Lugtenburg, Pieternella J ^x   Carrie, Christian ^y   Jaubert, Jérôme ^g   Henry Amar, Michel ^c   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT BERGONIÉ   (France)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e UNIVERSITÉ LYON 1   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ CHU NANCY BRABOIS   (France)

^j CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^k CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^l Cliniques Universitaires Saint Luc ^*  (France)

^m CENTRE HENRI BECQUEREL   (France)

ⁿ HENRI MONDOR HOSPITAL   (France)

^o RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^p LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^q CATHARINA HOSPITAL   (Netherlands)

^r PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^s UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^t CAEN UNIVERSITY HOSPITAL   (France)

^u CENTRE HOSPITALIER DE CHAMBÉRY   (France)

^v UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^w PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^x NETHERLANDS CANCER INSTITUTE   (Netherlands)

^y Ignatius Hospital   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; MOPP ABV PROTOCOL; MOPP-ABV PROTOCOL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EARLY CANCER; FEMALE; FOLLOW UP; HEART INFARCTION; HODGKIN DISEASE; HUMAN; INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY; REMISSION; SURVIVAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHATIC IRRADIATION; MALE; MECHLORETHAMINE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; RADIOTHERAPY; REMISSION INDUCTION; SURVIVAL ANALYSIS; VINBLASTINE; VINCRISTINE;

EID: 35848959692     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa064601     Document Type: Article

References (21)

1. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006;24:3128-35.
2. Eghbali H, Raemaekers J, Carde P, EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol 2005;66:Suppl:135-40.
3. Klimo P, Connors JM. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP-ABV Hybrid program. Semin Hematol 1988;25:Suppl 2:34-40.
4. Lee CK, Bloomfield CD, Goldman AI, Levitt SH. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer 1980;46:2403-9.
5. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6. [Erratum, J Clin Oncol 1990;8:1598.]
6. Rothman KJ, Boice JD Jr. Epidemiologic analysis with a programmable calculator. Boston: Epidemiology Resources, 1982.
7. Stata statistical software, release 8.2. College Station, TX: Stata, 2004.
8. StatXact statistical software for exact nonparametric inference, release 6.0. Cambridge, MA: Cytel Software, 2004.
9. Herson J. Predictive probability for early termination plans for phase II clinical trials. Biometrics 1979;35:775-83.
10. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001;19:4238-44.
11. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extendedfield radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007;25:3495-502.
12. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:3601-8.
13. Anselmo AP, Cavalieri E, Osti FM, et al. Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy. Anticancer Res 2004;24:4045-50.
14. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004;22:2835-41.
15. Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100:1989-96.
16. Diehl V, Brillant C, Engert A, et al. Reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: interim analysis of the HD10 trial of the GHSG. Blood 2004;104:1307. abstract.
17. Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol Suppl 2005;66:90-7.
18. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765-71.
19. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483-9.
20. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastin, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:62-8.
21. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stages Hodgkin's lymphoma: National Cancer Institute of Canada Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634-42.